Furthermore, a study published in 2022 documented a slight trend in increased PD-L1 expression correlating with better outcomes and growth stabilization in pembrolizumab-treated meningioma patients ( 20 ).
← all excerpts
Case Report: Advanced grade 2 meningioma with <i>PBRM1</i> inactivation with prolonged response to immunotherapy.
1
—
—